The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands

Vaccine

Volumn 29, Issue 48, 2011, Pages 8929-8936

  Bogaards, Johannes A ^a,b   Coupé, Veerle M H ^a   Meijer, Chris J L M ^a   Berkhof, Johannes ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Cervical cancer; Cost effectiveness; Human papillomavirus; Simulation model; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CHILD; COST EFFECTIVENESS ANALYSIS; CROSS PROTECTION; DRUG COST; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 58; INFECTION RISK; MAJOR CLINICAL STUDY; NETHERLANDS; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; UTERINE CERVIX CANCER; VACCINATION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; COST-BENEFIT ANALYSIS; CROSS PROTECTION; FEMALE; HUMANS; MASS VACCINATION; MIDDLE AGED; MODELS, THEORETICAL; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 82455171898     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.055     Document Type: Article

References (47)

1. Parkin D.M., Bray F. The burden of HPV-related cancers. Vaccine 2006, 24(Suppl. 3). S3/11-25.
2. Franco E.L., Duarte-Franco E., Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001, 164:1017-1025.
3. Bulk S., Visser O., Rozendaal L., Verheijen R.H., Meijer C.J. Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. Br J Cancer 2003, 89:834-839.
4. van der Aa M.A., Pukkala E., Coebergh J.W., Anttila A., Siesling S. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int J Cancer 2008, 122:1854-1858.
5. Sasieni P., Adams J., Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003, 89:88-93.
6. Arbyn M., Raifu A.O., Weiderpass E., Bray F., Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009, 45:2640-2648.
7. de Kok I.M., van der Aa M.A., van Ballegooijen M., Siesling S., Karim-Kos H.E., van Kemenade F.J., et al. Trends in cervical cancer in the Netherlands until 2007: has the bottom been reached?. Int J Cancer 2011, 128:2174-2181.
8. Rambout L., Hopkins L., Hutton B., Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007, 177:469-479.
9. Bogaards J.A., Coupé V.M., Xiridou M., Meijer C.J., Wallinga J., Berkhof J. Long-term impact of HPV vaccination on infection rates, cervical abnormalities and cancer incidence. Epidemiology 2011, 22:505-515.
10. Leask J., Jackson C., Trevena L., McCaffery K., Brotherton J. Implementation of the Australian HPV vaccination program for adult women: qualitative key informant interviews. Vaccine 2009, 27:5505-5512.
11. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007, 369:1861-1868. Future II Study Group.
12. Paavonen J., Naud P., Salmerón J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
13. Bogaards J.A., Xiridou M., Coupé V.M., Meijer C.J., Wallinga J., Berkhof J. Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus. Am J Epidemiol 2010, 171:817-825.
14. Boot H.J., Wallenburg I., de Melker H.E., Mangen M.J., Gerritsen A.A., van der Maas N.A., et al. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine 2007, 25:6245-6256.
15. Coupé V.M., van Ginkel J., de Melker H.E., Snijders P.J., Meijer C.J., Berkhof J. HPV16/18 vaccination to prevent cervical cancer in the Netherlands: model-based cost-effectiveness. Int J Cancer 2009, 124:970-978.
16. Bulkmans N.W., Berkhof J., Rozendaal L., van Kemenade F.J., Boeke A.J., Bulk S., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007, 370:1764-1772.
17. Bulkmans N.W., Berkhof J., Bulk S., Bleeker M.C., van Kemenade F.J., Rozendaal L., et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007, 96:1419-1424.
18. De Graaf H., Meijer S., Poelman J., Vanwesenbeeck I. Sex below the age of 25: sexual health of youth in the Netherlands in 2005 2006, Eburon Academic Publishers, Delft, [Rutgers N[isso Groep studies, no. 7, in Dutch].
19. Sexual health in the Netherlands in 2006 2006, Eburon Academic Publishers, Delft, [Rutgers Nisso Groep studies, no. 9, in Dutch]. F. Bakker, I. Vanwesenbeeck (Eds.).
20. Coupé V.M., Berkhof J., Bulkmans N.W., Snijders P.J.F., Meijer C.J. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008, 98:646-651.
21. Rebolj M., van Ballegooijen M., Berkers L.M., Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007, 120:806-812.
22. van den Akker-van Marle M.E., van Ballegooijen M., van Oortmarssen G.J., Boer R., Habbema J.D. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002, 94:193-204.
23. Ensing E, Steen M, Laferte R, Zonnenberg I, de Hoogh P. Opkomst HPV-vaccinaties per 31 december 2010. Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu; 2011 [in Dutch].
24. Berkhof J., de Bruijne M.C., Zielinksi G.D., Bulkmans N.W., Rozendaal L., Snijders P.J., et al. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline of mild dyskaryosis. Int J Cancer 2006, 118:1759-1768.
25. van Ballegooijen M., Rebolj M., Essink-Bot M.L., Meerding W.J., Berkers L.M., Habbema D. De effecten en kosten van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland na de herstructurering 2006, Instituut Maatschappelijke Gezondheidszorg, Rotterdam, [in Dutch].
26. Mandelblatt J.S., Lawrence W.F., Womack S.M., Jacobson D., Yi B., Hwang Y.T., et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002, 287:2372-2381.
27. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004, 96:604-615.
28. Rodenburg-van Dieten HE. Richtlijnen voor farmaco-economisch onderzoek; evaluatie en actualisatie. Diemen: College voor Zorgverzekeringen; 2005 [in Dutch]. Available from: [accessed 10.06.11]. http://www.cvz.nl/binaries/live/cvzinternet/hst_content/nl/documenten/rapporten/2005/rpt0510+richtlijnen+fe-onderzoek.pdf.
29. WHO guide for standardization of economic evaluations of immunization programmes. Geneva: World Health Organization; 2008. Available from: [accessed at 10.06.11]. http://www.who.int/immunization_financing/tools/who_ivb_08_14_en.pdf.
30. Dorleans F., Giambi C., Dematte L., Cotter S., Stefanoff P., Mereckiene J., et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 2010, 15. pii:19730.
31. French K.M., Barnabas R.V., Lehtinen M., Kontula O., Pukkala E., Dillner J., et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer 2007, 96:514-518.
32. Kim J.J., Goldie S.J. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359:821-832.
33. Jit M., Choi Y.H., Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337:a769.
34. Dasbach E.J., Insinga R.P., Elbasha E.H. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008, 115:947-956.
35. Elbasha E.H., Dasbach E.J., Insinga R.P., Haupt R.M., Barr E. Age-based programs for vaccination against HPV. Value Health 2009, 12:697-707.
36. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000, 181:1911-1919.
37. Ho G.Y., Studentsov Y.Y., Bierman R., Burk R.D. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004, 13:110-116.
38. Steele J., Collins S., Wen K., Ryan G., Constandinou-Williams C., Woodman C.B. Measurement of the humoral immune response following an incident human papillomavirus type 16 or 18 infection in young women by a pseudovirion-based neutralizing antibody assay. Clin Vaccine Immunol 2008, 15:1387-1390.
39. Stanley M. Immune responses to human papillomavirus. Vaccine 2006, 24(Suppl. 1):S16-S22.
40. de Kok I.M., van Ballegooijen M., Habbema J.D. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2009, 101:1083-1092.
41. Coupé V.M., Meijer C.J., Berkhof J. Re cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2010, 102:538.
42. Postma M.J. Cost-effectiveness analysis of human papillomavirus (HPV) vaccination in the Netherlands: recent publication reinforces favorable cost-effectiveness despite misleading conclusion. Vaccine 2010, 28:873-874.
43. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
44. Wheeler C.M., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Perez G., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009, 199:936-944.
45. Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis 2009, 199:919-922.
46. van Lier EA, Oomen PJ, Giesbers H, Drijfhout IH, de Hoogh PA, de Melker HE. Vaccinatiegraad Rijksvaccinatieprogramma Nederland. Bilthoven: RIVM; 2011 [in Dutch]. Available from: [Accessed 01.09.2011]. http://www.rivm.nl/bibliotheek/rapporten/210021014.pdf.
47. Franceschi S., Denny L., Irwin K.L., Jeronimo J., Lopalco P.L., Monsonego J., et al. Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer 2011, 128:2765-2774.